Selinexor
- Generic Name
- Selinexor
- Brand Names
- Xpovio 100 Mg Once Weekly Carton, Nexpovio
- Drug Type
- Small Molecule
- Chemical Formula
- C17H11F6N7O
- CAS Number
- 1393477-72-9
- Unique Ingredient Identifier
- 31TZ62FO8F
- Background
Selinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound. Selinexor, in combination with bortezomib and dexamethasone, is currently approved for the treatment of multiple myeloma, a type of cancer formed from antibody-producing plasma cells. This condition is typically treated with high dose bortezomib and dexamethasone chemothe...
- Indication
Selinexor is indicated in combination with bortezomib and dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. Selinexor is also indicated in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma in adult patients who have received at least four prior therapi...
- Associated Conditions
- Multiple Myeloma (MM), Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Relapsed Diffuse large B-cell lymphoma NOS
- Associated Therapies
- -
The Targeted Pulse: Explore Highlighted Updates From This Year's SABCS on Breast
Palbociclib + standard therapy improved progression-free survival in hormone receptor–positive, HER2-positive metastatic breast cancer. No significant overall survival benefit observed among CDK4/6 inhibitor combinations in hormone receptor-positive/HER2-negative breast cancer. Patritumab deruxtecan showed similar efficacy to multiagent chemotherapy in high-risk hormone receptor-positive, HER2-negative breast cancer. Ciltacabtagene autoleucel achieved 100% complete response in high-risk smoldering multiple myeloma. Selinexor + ruxolitinib showed efficacy in myelofibrosis patients previously treated with ruxolitinib.
Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of ...
Karyopharm Therapeutics appoints Brendan Strong as Senior VP of Investor Relations and Corporate Communications, leveraging his experience in biopharmaceuticals and investor relations.
Karyopharm Therapeutics Provides Endometrial Cancer Program Update
Karyopharm Therapeutics Inc. is discussing its Phase 3 XPORT-EC-042 trial with the FDA regarding endometrial cancer treatment, leading to a decision not to discuss the program at the Piper Sandler 36th Annual Healthcare Conference. Updates will follow the FDA meeting.
Antengene Announces XPOVIO®'s New Indication Included in 2024 China National ...
Antengene announces XPOVIO® (selinexor) inclusion in China's 2024 NRDL for R/R DLBCL, following its approval in July 2024. This marks XPOVIO®'s second indication in China to be covered by NRDL, enhancing patient access to the drug.
Karyopharm to Present Selinexor Data at the 66th American Society of Hematology Annual
Karyopharm Therapeutics to present selinexor data at the 66th ASH Annual Meeting, showcasing ongoing work in multiple myeloma and myelofibrosis.
Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress
Karyopharm reports Q3 2024 revenue of $38.8M, with $29.5M from U.S. XPOVIO. FDA alignment changes SENTRY trial endpoint to Abs-TSS. Full-year 2024 revenue guidance narrowed to $145M-$155M. CEO highlights XPOVIO growth and clinical trial progress.
Karyopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a ...
Karyopharm to host investor event on Oct 31, 2024, featuring KOLs Dr. Raajit Rampal and Dr. John Mascarenhas, with a favorable study design update on the Phase 3 SENTRY study in JAKi naive myelofibrosis.
Fennec Pharmaceuticals Strengthens Executive Leadership
Fennec Pharmaceuticals appoints Pierre S. Sayad as Chief Medical Officer, Terry Evans as Chief Commercial Officer, and Christiana Cioffi as Chief Strategy Officer to strengthen its executive team and accelerate the commercialization of PEDMARK, the first therapy to reduce ototoxicity risk from cisplatin treatment in pediatric patients.
Antengene receives Thailand FDA approval to commercialize Xpovio in Thailand
Antengene's Xpovio (selinexor) receives Thailand FDA approval for multiple myeloma treatments, expanding its reach in APAC. Xpovio, an orally-available selective XPO1 inhibitor, aims to improve clinical management of MM in Thailand and other ASEAN markets. Antengene plans further expansion and development of Xpovio combinations for various cancers.
Investigator-led oncology cell therapy trial terminated
Iovance Biotherapeutics' MDA-TIL trial terminated due to lack of efficacy, leading to drops in Phase Transition Success Rates (PTSR) in various cancers. Sention Therapeutics' ST-1891 and Armata Pharmaceuticals' APPA-02 trials completed successfully in hypothyroidism and bronchiectasis, respectively, boosting their PTSRs. Karyopharm Therapeutics' Xpovio trial in metastatic melanoma and Worg Pharmaceuticals Hangzhou's WP-1302 trial in Graves' disease were terminated, affecting their PTSRs negatively.
Related Clinical Trials:
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath